Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.
NCT02422940
·
clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
294
Enrollment
INDUSTRY
Sponsor class
Conditions
Post-ischemic Stroke
Interventions
DRUG:
dalfampridine-ER 7.5 mg
DRUG:
dalfampridine-ER 10 mg
Sponsor
Acorda Therapeutics